Zhai Guanxing, Lu Lu, Lu Huili, Chen Daijie
College of Life Sciences, Shanghai Normal University, Shanghai 200234, China.
School of Biological Engineering, East China University of Science and Technology, Shanghai 200237, China.
Sheng Wu Gong Cheng Xue Bao. 2019 Jul 25;35(7):1174-1183. doi: 10.13345/j.cjb.190040.
With the rapid development of antibody genetic engineering, bispecific antibody technology has been advanced. They are capable of binding two or more different epitopes simultaneously, thus offering specific advantages over natural monoclonal antibodies in immunotherapy. Bispecific antibodies have been successfully used in cancer therapy (e.g. melanoma, Hodgkin's lymphoma, liver cancer, and stomach cancer) and inflammation therapy (e.g. rheumatoid arthritis, psoriasis and Crohn's disease), but are still in their early stage for viral immunotherapy. In this study, we reviewed the research progress of bispecific antibodies for immunotherapy of virus infections, especially those with good effects in vivo and in vitro, to provide references for the research and development of bispecific antibodies for antivirus treatment.
随着抗体基因工程的快速发展，双特异性抗体技术也取得了进步。它们能够同时结合两个或更多不同的表位，因此在免疫治疗中比天然单克隆抗体具有特定优势。双特异性抗体已成功应用于癌症治疗（如黑色素瘤、霍奇金淋巴瘤、肝癌和胃癌）和炎症治疗（如类风湿性关节炎、银屑病和克罗恩病），但在病毒免疫治疗方面仍处于早期阶段。在本研究中，我们综述了用于病毒感染免疫治疗的双特异性抗体的研究进展，特别是那些在体内和体外均具有良好效果的双特异性抗体，为抗病毒治疗双特异性抗体的研发提供参考。
